Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

BREAST CANCER

Predicting late recurrence in ER-positive breast cancer

Identification of factors predicting recurrence of breast cancer is a long-standing goal, ranging from classical clinicopathological factors through to immunohistochemical assays of receptor levels and, more recently, the expression levels of several genes. A new paper now explores novel expression markers, especially for late recurrence of oestrogen receptor-positive breast cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836–1846 (2017).

    Article  Google Scholar 

  2. 2.

    Cuzick, J. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J. Clin. Oncol. 29, 4273–4278 (2011).

    Article  Google Scholar 

  3. 3.

    Dowsett, M. et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J. Clin. Oncol. 36, 1941–1948 (2018).

    CAS  Article  Google Scholar 

  4. 4.

    Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288–300 (2019).

    CAS  Article  Google Scholar 

  5. 5.

    Sestak, I. et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4, 545–553 (2018).

    Article  Google Scholar 

  6. 6.

    Cheng, L. et al. Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol. Biomarkers Prev. 21, 800–809 (2012).

    Article  Google Scholar 

  7. 7.

    Hamadeh, I. S. et al. Personalizing aromatase inhibitor therapy in patients with breast cancer. Cancer Treat. Rev. 70, 47–55 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399–404 (2019).

    CAS  Article  Google Scholar 

  9. 9.

    Gellert, P. et al. Breast cancer treatment: a review. JAMA 321, 288–300 (2019).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jack Cuzick.

Ethics declarations

Competing interests

The author declares that he is a consultant for Myriad Genetics, who market the EndoPredict assay (EPclin).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cuzick, J. Predicting late recurrence in ER-positive breast cancer. Nat Rev Clin Oncol 16, 406–408 (2019). https://doi.org/10.1038/s41571-019-0228-y

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing